|
The ABL Advisor Deal Tables
SELECTED TRANSACTION DETAILS
NovaQuest Capital Management Provides $50MM Royalty Monetization Financing to FibroGen
Tuesday, November 8, 2022
|
Lenders/Participants
|
NovaQuest Capital Management [Lender]
|
|
Structure
|
Royalty Monetization Financing
|
|
Amount
|
$50.000
Million
|
|
Borrower(s)
|
FibroGen
|
|
Description
|
A royalty monetization financing with NovaQuest Capital Management that will result in proceeds to FibroGen in the amount of $50 million, bringing non-dilutive capital to drive innovation and growth. The deal includes the following: $50 million cash upfront in exchange for 22.5% of future EVRENZOTM royalties in the territories partnered with Astellas; The aggregate payments to be received by NovaQuest Capital under this Agreement are capped at certain fixed multiples of the upfront payment based upon time. Once NovaQuest receives an aggregate of either:$100 million (2.0x the upfront) by the end of 2028, or $112.5 million (2.25x the upfront) by the end of 2029, or $125 million (2.50x the upfront) by the end of 2030.
|
|
Industry
|
Biopharmaceuticals
|
| Related Tags |
FibroGen, NovaQuest Capital Management
|
ABL Advisor
Deal Tables
2025
|
|
|
|